RadNet Stock (NASDAQ:RDNT)
Previous Close
$79.58
52W Range
$31.55 - $93.65
50D Avg
$69.29
200D Avg
$57.47
Market Cap
$5.85B
Avg Vol (3M)
$568.90K
Beta
1.75
Div Yield
-
RDNT Company Profile
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
RDNT Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Software and Teleradiology | $18.08M | $14.24M | - |
| Workers' Compensation/Personal Injury1 | $47.36M | $51.34M | $44.23M |
| Medicare1 | $363.86M | $311.12M | $280.91M |
| Medicaid1 | $43.17M | $38.28M | $34.73M |
| Health Care, Patient Service Other | $42.25M | $31.85M | $19.40M |
| Health Care, Other | $20.11M | $19.43M | $13.85M |
| Health Care, Management Service | $17.94M | $22.23M | $19.63M |
| Commercial Insurance1 | $897.95M | $785.13M | $743.46M |
| Capitation Arrangements | $153.43M | $152.04M | $148.33M |
| Imaging On Call | - | - | $10.53M |
| Health Care, Patient Service | - | - | $1.17B |
Fiscal year ends in Dec 23 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| GTH | Genetron Holdings Limited |
| XGN | Exagen Inc. |
| LMDX | LumiraDx Limited |
| SERA | Sera Prognostics, Inc. |
| BNR | Burning Rock Biotech Limited |
| QGEN | Qiagen N.V. |
| ACRS | Aclaris Therapeutics, Inc. |
| NEOG | Neogen Corporation |
| OLK | Olink Holding AB (publ) |
| BDSX | Biodesix, Inc. |
| FONR | FONAR Corporation |
| MYGN | Myriad Genetics, Inc. |
| SHC | Sotera Health Company |